Poeta G.D.,University of Rome Tor Vergata |
Principe M.I.D.,University of Rome Tor Vergata |
Zucchetto A.,Clinical and Experimental Onco Hematology Research Unit |
Luciano F.,University of Rome Tor Vergata |
And 15 more authors.
Haematologica | Year: 2012
Background: CD69 is expressed in several hemopoietic cells and is an early activation marker in chronic lym-phocytic leukemia. Chronic lymphocytic leukemia is a clinically heterogeneous disease which needs novel prognostic parameters which can be easily and efficiently managed. Design and Methods: We investigated CD69 by flow cytometry in a series of 417 patients affected by chronic lym-phocytic leukemia and compared this to other biological and clinical prognosticators. Results: CD69 was associated with Rai stages (P=0.00002), b2-microglobulin (P=0.0005) and soluble CD23 (P<0.0001). CD69 and ZAP-70 (P=0.018) or CD38 (P=0.00015) or immunoglobulin variable heavy chain gene mutations (P=0.0005) were also significantly correlated. Clinically, CD69 positive chronic lymphocytic leukemias received chemotherapy more frequently (74%; P<0.0001), and presented a shorter duration of response after fludarabine plus rituximab (P=0.010) as well as shorter progression free survival and overall survival (P<0.0001). CD69 demonstrated true additive prognostic properties, since the CD69+ plus ZAP-70+ or CD38+ or immunoglobulin variable heavy chain gene unmutated patients had the worst progression free survival and overall survival (P<0.0001). Interestingly, low CD69 expression was necessary to correctly prognosticate the longer progression free survival of patients with a low tumor burden of b2-microglobulin (P=0.002), of soluble CD23 (P=0.020), or of Rai stages 0-I (P=0.005). CD69 was confirmed to be an independent prognostic factor in multivariate analysis of progression free survival (P=0.017) and overall survival (P=0.039). Conclusions: Our data indicate that CD69 is significantly correlated with poor clinical and biological prognostic factors and is confirmed to be an independent disease prognosticator. This supports its introduction in a routine laboratory assessment and, possibly, in a prognostic scoring system for chronic lymphocytic leukemia, after an adequate standardization process. © 2012 Ferrata Storti Foundation.